FDA Approves Entanercept (Enbrel®) for treatment of Psoriatic Arthritis
The U.S. Food and Drug Administration (FDA) approved Enbrel®(Etanercept) for the reduction in signs and symptoms in patients with active psoriatic arthritis. Currently approved for use in rheumatoid arthritis, Enbrel binds the pro-inflammatory cytokine, tumor necrosis factor (TNF) . (read more about TNF inhibitors)
Approval was based on the positive results of a Phase II clinical trial involving 60 patients and a Phase III trial of 205 patients, both comparing the efficacy of enbrel vs. placebo for treatment in patients with psoriatic arthritis.